Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
12 Results for "
adverse events
" in MedChemExpress (MCE) Product Catalog:
Products (12)
12 Results for "adverse events" in MCE Product Catalog:
3
Target:
Research Areas:
3
Target:
Research Areas:
1
1 Cited Publications
Cat. No.: HY-P99016B
CAS No.: 1346452-25-2
Research Areas:
Cat. No.: HY-P9975
CAS No.: 906068-56-2
Synonyms: TGN1412; TAB08
Target:
Research Areas:
Cat. No.: HY-P991628
Synonyms: PF-08634404
Target:
Research Areas:
Cat. No.: HY-172435
CAS No.: 1431754-15-2
Synonyms: AGN-232411; AG-80308; AGN-411
Target:
Research Areas:
Rezuforimod (AGN-232411; AG-80308) is an ophthalmic solution targeting the formyl peptide receptor (FPR) pathway. Rezuforimod exerts anti-inflammatory effects by targeting the formyl peptide receptor pathway. Administered topically, Rezuforimod significantly reduces the corneal conjunctival staining score and improves ocular discomfort symptoms, with no serious adverse events reported and favorable overall safety profile. Rezuforimod shows remarkable potential to serve as a novel therapeutic option for dry eye disease .
Cat. No.: HY-172242
CAS No.: 1887236-33-0
Target:
Research Areas:
Verducatib (BI 1291583) is an orally active inhibitor of cathepsin C (also known as DPP1). Verducatib restores the protease-inhibitor balance by inhibiting the activation of neutrophil serine proteases, thereby alleviating pulmonary inflammation and regulating infection responses. Verducatib significantly reduces the risk (including severe exacerbations) and frequency of acute exacerbations in bronchiectasis (BE). Verducatib also improves lung function and quality of life, and shortens the duration of antibiotic use. The overall incidence of adverse events of Verducatib is comparable to that of placebo, with only slightly more mild-to-moderate cutaneous adverse events observed in the high-dose group, demonstrating promising clinical application potential .
Cat. No.: HY-W923642
CAS No.: 474923-21-2
Target:
Research Areas:
Sphingomyelin (d18:1/12:0) is a metabolomic biomarker. Sphingomyelin (d18:1/12:0) exhibits favorable diagnostic properties and may facilitate the early detection and targeted prevention of dyslipidemia-related adverse cardiovascular events .
Cat. No.: HY-W016083
CAS No.: 93-20-9
Synonyms: β-Naphthoxyethanol
Target:
Research Areas:
Anavenol (β-Naphthoxyethanol) is an anesthetic. Anavenol exerts anesthetic effects on horses. Anavenol can be used in studies on adverse events associated with equine anesthesia .
Cat. No.: HY-162884
CAS No.: 2208619-76-3
Target:
Research Areas:
EcGUS-IN-1 (Compound E-9) is a non-competitive β-glucuronidase inhibitor, with an IC50 of 2.68 μM and a Ki value of 1.64 μM. EcGUS-IN-1 can improve gastrointestinal adverse events (GIAE) caused by Escherichia coli infection by inhibiting E. coli β-glucuronidase activity .
Cat. No.: HY-P992380
Target:
Research Areas:
Cat. No.: HY-L140
232 compounds
Withdrawal or delisting drugs refer to drugs that are recalled or discontinued from the market due to low efficiency, serious side effects, financial and regulatory problems and other reasons. Once the drug is withdrawn from the market, it will cause heavy losses to the original research company that invested a lot of time, finance and other costs to develop the drug.
Adverse drug reaction (ADR) is the main reason for drug withdrawal from the market. ADR refers to the unexpected effects caused by the reasons such as the target-directed interaction during the treatment. However, studying the mechanism of these ADRs may just be a breakthrough in finding new indications. For example, thalidomide, the protagonist of the drug damage event that caused numerous "seal babies" deformed infants, was found to be due to the degradation of a transcription factor - SALL4 after delisting, which made thalidomide have a new clinical application. In 1998, it was approved by FDA for the treatment of leprosy nodular erythema, and in 2006, it was approved for the treatment of multiple myeloma. ADR study of delisted drugs can not only avoid the loss of drug development in advance but also bring hope to new indications.
MCE has sorted out 232 drug compounds withdrawn from the market through FDA, EMA and other authoritative platforms. Each compound has withdrawal records in at least one country/market. It is a useful tool for conducting research on drug side effects or drug toxicity mechanisms and discovering new indications of drugs.
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
